ASO Author Reflections: Personalized Surgery in Recurrent Ovarian Cancer Patients

Estati, Felipe Leonardo; Baiocchi, Glauco; Costa, Alexandre André Balieiro Anastácio da

doi:10.1245/s10434-020-09368-8

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the role of secondary cytoreductive surgery (SeCRS) remains a matter of debate. [3][4][5] Now three randomized Phase 3 trials are underway to evaluate the effect of SeCRS followed by chemotherapy in patients with recurrent ovarian cancer, but these studies have not reached a consistent conclusion. [6][7][8] Primary or interval cytoreductive surgery (pCRS or iCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new form of treatment for EOC.…”

Section: Introductionmentioning

confidence: 99%

“…In the past few years, substantial progress has been achieved in the treatment of platinum‐sensitive EOC with therapies such as immune checkpoint inhibitors, polyadenosine diphosphate‐ribose polymerase (PARP) inhibitors, and antiangiogenic drugs. However, the role of secondary cytoreductive surgery (SeCRS) remains a matter of debate 3–5 . Now three randomized Phase 3 trials are underway to evaluate the effect of SeCRS followed by chemotherapy in patients with recurrent ovarian cancer, but these studies have not reached a consistent conclusion 6–8 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer

Dong

Zhang

Gong

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

To evaluate the effect of secondary cytoreductive surgery (SeCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer patients. Methods: This retrospective study analyzed a prospective database. We collected information of 389 patients who were diagnosed with recurrent epithelial ovarian cancer. All patients underwent SeCRS with or without HIPEC. Overall survival and progression-free survival (PFS) were used to evaluate the treatment effectiveness.Results: Of the 389 patients collected, 123 underwent primary or interval cytoreductive surgery at initial treatment and SeCRS at recurrence (Group A), 130 underwent primary or interval cytoreductive surgery at initial and SeCRS plus HIPEC at recurrence (Group B), and 136 underwent primary or interval cytoreductive surgery plus HIPEC at initial and SeCRS plus HIPEC at recurrence (Group C). The median overall survival for Groups A, B, and C were 49.1 months (95% confidence interval [CI]: 47.6-50.5), 56.0 months (95% CI: 54.2-57.7), and 64.4 months (95% CI: 63.1-65.6), respectively. The median PFS for Groups A, B, and C were 13.1 months (95% CI: 12.6-13.5), 15.0 months (95% CI: 14.2-15.7), and 16.8 months (95% CI: 16.1-17.4), respectively. There were no significant difference in incidence and grade of adverse events among groups. Conclusions: This study suggested that SeCRS plus HIPEC followed by chemotherapy resulted in longer overall survival and PFS than only SeCRS followed by chemotherapy in patients with recurrent ovarian cancer, especially in patients who were treated with repeat HIPEC.

show abstract